Tags

Type your tag names separated by a space and hit enter

Covert dyskinesia associated with aripiprazole: a case report and review of the literature.
Clin Neuropharmacol. 2013 Jul-Aug; 36(4):128-30.CN

Abstract

The atypical antipsychotic agents are felt by many to have a lower risk of inducing the development of dyskinetic movements than the conventional antipsychotic agents agents such as haloperidol and fluphenazine. However, that does not mean that treatment with the atypical antipsychotic agents carries no risk of developing dyskinesias. To the contrary, all of the atypical antipsychotic agents, including aripiprazole, have been associated with the induction of dyskinetic movements. We will present the case of a patient who developed a covert dyskinesia that manifested shortly after the discontinuation of aripiprazole. We will review the use of aripiprazole and the adverse effects most commonly associated with its use. We will also discuss the risk factors associated with the development of tardive dyskinesia and review the different clinical variations (withdrawal dyskinesia, covert dyskinesia, tardive diskinesia) of medication-induced dyskinesias.

Authors+Show Affiliations

Department of Psychiatry and Behavioral Neurosciences, College of Medicine, University of South Florida, Tampa, FL, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article
Review

Language

eng

PubMed ID

23860346

Citation

Moseley, Carrie N., et al. "Covert Dyskinesia Associated With Aripiprazole: a Case Report and Review of the Literature." Clinical Neuropharmacology, vol. 36, no. 4, 2013, pp. 128-30.
Moseley CN, Simpson-Khanna HA, Catalano G, et al. Covert dyskinesia associated with aripiprazole: a case report and review of the literature. Clin Neuropharmacol. 2013;36(4):128-30.
Moseley, C. N., Simpson-Khanna, H. A., Catalano, G., & Catalano, M. C. (2013). Covert dyskinesia associated with aripiprazole: a case report and review of the literature. Clinical Neuropharmacology, 36(4), 128-30. https://doi.org/10.1097/WNF.0b013e31829b99d9
Moseley CN, et al. Covert Dyskinesia Associated With Aripiprazole: a Case Report and Review of the Literature. Clin Neuropharmacol. 2013 Jul-Aug;36(4):128-30. PubMed PMID: 23860346.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Covert dyskinesia associated with aripiprazole: a case report and review of the literature. AU - Moseley,Carrie N, AU - Simpson-Khanna,Heather A, AU - Catalano,Glenn, AU - Catalano,Maria C, PY - 2013/7/18/entrez PY - 2013/7/19/pubmed PY - 2014/2/27/medline SP - 128 EP - 30 JF - Clinical neuropharmacology JO - Clin Neuropharmacol VL - 36 IS - 4 N2 - The atypical antipsychotic agents are felt by many to have a lower risk of inducing the development of dyskinetic movements than the conventional antipsychotic agents agents such as haloperidol and fluphenazine. However, that does not mean that treatment with the atypical antipsychotic agents carries no risk of developing dyskinesias. To the contrary, all of the atypical antipsychotic agents, including aripiprazole, have been associated with the induction of dyskinetic movements. We will present the case of a patient who developed a covert dyskinesia that manifested shortly after the discontinuation of aripiprazole. We will review the use of aripiprazole and the adverse effects most commonly associated with its use. We will also discuss the risk factors associated with the development of tardive dyskinesia and review the different clinical variations (withdrawal dyskinesia, covert dyskinesia, tardive diskinesia) of medication-induced dyskinesias. SN - 1537-162X UR - https://www.unboundmedicine.com/medline/citation/23860346/Covert_dyskinesia_associated_with_aripiprazole:_a_case_report_and_review_of_the_literature_ L2 - https://doi.org/10.1097/WNF.0b013e31829b99d9 DB - PRIME DP - Unbound Medicine ER -